GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » LT-Debt-to-Total-Asset

APM (Aptorum Group) LT-Debt-to-Total-Asset : 0.18 (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aptorum Group's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.18.

Aptorum Group's long-term debt to total assets ratio increased from Jun. 2023 (0.01) to Jun. 2024 (0.18). It may suggest that Aptorum Group is progressively becoming more dependent on debt to grow their business.


Aptorum Group LT-Debt-to-Total-Asset Historical Data

The historical data trend for Aptorum Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group LT-Debt-to-Total-Asset Chart

Aptorum Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.27 0.05 - 0.03 0.15

Aptorum Group Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.03 0.01 0.15 0.18

Aptorum Group LT-Debt-to-Total-Asset Calculation

Aptorum Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=3.158/20.64
=0.15

Aptorum Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=3.211/17.705
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptorum Group  (NAS:APM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Aptorum Group LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Aptorum Group's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptorum Group Business Description

Traded in Other Exchanges
N/A
Address
17 Hanover Square, London, GBR, W1S 1BN
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Aptorum Group Headlines

From GuruFocus